Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706863 | 0.77 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ATSHR | |
| SCHEMBL3706859 | 0.77 | MEN1 (0.38) | MEN1CYP3A4CYP2D6KMT2ATSHR | |
| SCHEMBL8469952 | 0.77 | P2RX7 (0.40) | LTA4HTSHR | |
| SCHEMBL18322032 | 0.77 | AKR1B1 (0.40) | MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL18322171 | 0.77 | AKR1B1 (0.40) | MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL18322029 | 0.77 | AKR1B1 (0.40) | MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL17468803 | 0.76 | CYP3A4 (0.49) | MEN1CYP3A4CYP2D6KMT2ATSHR | |
| SCHEMBL3750295 | 0.75 | MEN1 (0.36) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL3750291 | 0.75 | MEN1 (0.36) | MEN1CYP3A4CYP2D6KMT2ADRD2 | |
| SCHEMBL18322196 | 0.73 | LTA4H (0.33) | MEN1CYP3A4CYP2D6KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | GPBAR1, GPR35, GRPR | MEN1 4279/4885CYP3A4 2595/4885CYP2D6 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.